5 Key Takeaways

• 1

  Aptamers are short nucleic acid molecules that can bind specific targets, functioning similarly to chemical antibodies.

• 2

  Traditional SELEX for aptamer development is labor-intensive and may yield candidates that perform poorly in complex clinical samples.

• 3

  Newer methods, including microfluidic platforms and AI, aim to enhance aptamer selection speed and performance.

• 4

  Aptamer-based diagnostics require rigorous validation, including assessments of structure, binding strength, and specificity.

• 5

  Despite advantages like chemical synthesis and stability, clinical translation of aptamers remains limited due to performance variability.